Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.35 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.35 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.35 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.35 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.35 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.32 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.32 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.32 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 2/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | NOX1 | Q9Y5S8 | 4/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3715669 | 0.87 | SNCA (0.38) | SNCAMPONOX1SLC6A3HTR1A | |
| Iodide SCHEMBL16496288 | 0.85 | KDM4E (0.34) | SNCAMPONOX1HTTGAA | |
| Bromide SCHEMBL3714202 | 0.85 | SNCA (0.39) | SNCAMPONOX1CHRM1DRD3 | |
| SCHEMBL11763196 | 0.85 | SNCA (0.41) | SNCANOX1SLC6A3SLC6A2HTT | |
| Iodide SCHEMBL16496354 | 0.83 | TDP1 (0.36) | SNCANOX1KCNH2GAATDP1 | |
| SCHEMBL1472458 | 0.82 | SNCA (0.39) | SNCANOX1HTTGAAMAPT | |
| SCHEMBL1472499 | 0.82 | SNCA (0.39) | SNCANOX1SLC6A3SLC6A2HTT | |
| SCHEMBL12592413 | 0.82 | SNCA (0.43) | SNCANOX1SLC6A3SLC6A2HTT | |
| SCHEMBL972682 | 0.81 | SNCA (0.46) | SNCANOX1SLC6A3SLC6A2HTT | |
| SCHEMBL1472475 | 0.81 | SNCA (0.38) | SNCANOX1HTTGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306576-A1 | COMPOUNDS AND METHODS RELATING THERETO | PHARMALUCIA LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| WO-2010097626-A2 | COMPOUNDS AND METHODS RELATING THERETO | PHARMALUCIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306576-A1 | COMPOUNDS AND METHODS RELATING THERETO | QSOX1, PYM1, SQOR | SLC6A3 356/4885CHRM2 453/4885HTR1A 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.